Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Blueprint Genetics | RCV001596876 | SCV001832372 | uncertain significance | not provided | 2019-11-30 | criteria provided, single submitter | clinical testing | |
Invitae | RCV001866250 | SCV002229224 | pathogenic | Camptomelic dysplasia | 2021-10-27 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This variant disrupts the p.Arg120 amino acid residue in SOX9. Other variant(s) that disrupt this residue have been observed in individuals with SOX9-related conditions (PMID: 24451061), which suggests that this may be a clinically significant amino acid residue. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt SOX9 protein function. This missense change has been observed in individual(s) with clinical features of SOX9-related conditions (Invitae). In at least one individual the variant was observed to be de novo. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces arginine, a(n) basic and polar amino acid, with leucine, a(n) neutral and non-polar amino acid, at codon 120 of the SOX9 protein (p.Arg120Leu). |